Central Pharmaceutical Joint Stock Company No3 (HNX:DP3)
Vietnam
· Delayed Price · Currency is VND 63,000
+700 (1.12%)
At close: Mar 5, 2026
HNX:DP3 Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 438,006 | 417,485 | 409,731 | 485,074 | 381,077 | Upgrade
|
| Revenue Growth (YoY) | 4.92% | 1.89% | -15.53% | 27.29% | -3.70% | Upgrade
|
| Cost of Revenue | 150,345 | 141,432 | 128,228 | 148,536 | 117,447 | Upgrade
|
| Gross Profit | 287,661 | 276,054 | 281,503 | 336,538 | 263,630 | Upgrade
|
| Selling, General & Admin | 117,174 | 139,372 | 144,618 | 208,717 | 151,491 | Upgrade
|
| Operating Expenses | 117,174 | 139,372 | 144,618 | 208,717 | 151,491 | Upgrade
|
| Operating Income | 170,487 | 136,682 | 136,885 | 127,821 | 112,139 | Upgrade
|
| Interest Expense | -694.75 | -161.5 | -1,594 | -6,475 | -449 | Upgrade
|
| Interest & Investment Income | 22,834 | 15,463 | 21,665 | 10,732 | 7,360 | Upgrade
|
| Currency Exchange Gain (Loss) | -64.63 | -133.63 | -15.04 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 262.86 | -97.52 | 60.97 | 4,412 | -839.85 | Upgrade
|
| EBT Excluding Unusual Items | 192,825 | 151,752 | 157,001 | 136,490 | 118,210 | Upgrade
|
| Gain (Loss) on Sale of Assets | 30 | 163.2 | 2.28 | - | - | Upgrade
|
| Pretax Income | 192,855 | 151,915 | 157,003 | 136,490 | 118,210 | Upgrade
|
| Income Tax Expense | 39,294 | 30,743 | 31,740 | 27,665 | 23,905 | Upgrade
|
| Net Income | 153,561 | 121,172 | 125,263 | 108,824 | 94,305 | Upgrade
|
| Net Income to Common | 153,561 | 121,172 | 125,263 | 108,824 | 94,305 | Upgrade
|
| Net Income Growth | 26.73% | -3.27% | 15.11% | 15.40% | -17.32% | Upgrade
|
| Shares Outstanding (Basic) | 21 | 21 | 21 | 23 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 21 | 21 | 23 | 21 | Upgrade
|
| Shares Change (YoY) | - | - | -5.00% | 5.27% | -0.00% | Upgrade
|
| EPS (Basic) | 7142.41 | 5635.90 | 5826.22 | 4808.40 | 4386.40 | Upgrade
|
| EPS (Diluted) | 7142.41 | 5635.90 | 5826.22 | 4808.40 | 4386.40 | Upgrade
|
| EPS Growth | 26.73% | -3.27% | 21.17% | 9.62% | -17.32% | Upgrade
|
| Free Cash Flow | 242,076 | 90,452 | 146,699 | 84,126 | 25,862 | Upgrade
|
| Free Cash Flow Per Share | 11259.39 | 4207.10 | 6823.21 | 3717.11 | 1202.91 | Upgrade
|
| Dividend Per Share | - | - | 3000.000 | - | 2400.000 | Upgrade
|
| Gross Margin | 65.67% | 66.12% | 68.70% | 69.38% | 69.18% | Upgrade
|
| Operating Margin | 38.92% | 32.74% | 33.41% | 26.35% | 29.43% | Upgrade
|
| Profit Margin | 35.06% | 29.02% | 30.57% | 22.43% | 24.75% | Upgrade
|
| Free Cash Flow Margin | 55.27% | 21.67% | 35.80% | 17.34% | 6.79% | Upgrade
|
| EBITDA | 182,044 | 149,542 | 150,864 | - | - | Upgrade
|
| EBITDA Margin | 41.56% | 35.82% | 36.82% | - | - | Upgrade
|
| D&A For EBITDA | 11,556 | 12,861 | 13,980 | - | - | Upgrade
|
| EBIT | 170,487 | 136,682 | 136,885 | 127,821 | 112,139 | Upgrade
|
| EBIT Margin | 38.92% | 32.74% | 33.41% | 26.35% | 29.43% | Upgrade
|
| Effective Tax Rate | 20.38% | 20.24% | 20.22% | 20.27% | 20.22% | Upgrade
|
| Revenue as Reported | 438,006 | 417,485 | 409,731 | 485,074 | 381,077 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.